Compare Gilead Sciences, Inc. (GILD) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Stryker Corporation — how do they compare? Gilead Sciences, Inc. trades at $136.45 (market cap $163.51B), while Stryker Corporation trades at $320 (market cap $121.31B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SYK | |
|---|---|---|
Market Cap | $163.51B | $121.31B |
Sector | Health | Technology |
52-Week High | $155.80 | $403.53 |
52-Week Low | $108.22 | $282.58 |
Enterprise Value | $178.05B | $133.07B |
Dividend Yield | 2.49% | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Stryker (SYK) trades at $329.38, up 5.84% in the last session, yet technical indicators signal a bearish trend. The company reported a Q1 2026 earnings miss due to a temporary cyber disruption but maintained full-year guidance, with strong profitability margins and robust cash flow. Recent news highlights expansion of its Mako robotics platform, reinforcing its innovation-led growth strategy in the medical technology sector.
The investment outlook is positive based on strong fundamentals and analyst consensus, but near-term risks include competitive pressures and execution challenges. With a consensus price target of $388.44 representing ~18% upside, the stock offers value for long-term investors, though volatility may persist until Q2 earnings clarify the post-disruption recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
